• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Conferences

Conferences

Designing and Engineering Antibodies to Mutable Protein Targets

April 14, 2019 | World Vaccine Congress

Designing and Engineering Antibodies to Mutable Protein Targets

Greg Babcock

Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering

April 11, 2019 | PEGS
Bohnuud, et. al.

Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering

Tanggis Bohnuud, Andrew Wollacott, Karthik Viswanathan

>SEE POSTER

Antibody Design and Engineering Through Integration of Computational and Experimental Methods

February 26, 2019 | Antibody Engineering & Therapeutics, Asia

Antibody Design and Engineering Through Integration of Computational and Experimental Methods

Karthik Viswanathan

Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data

January 15, 2019 | Peptalk

Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data

Andrew Wollacott

Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties

January 15, 2019 | Peptalk
Booth, et. al.

Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties

Brain J Booth, Boopathy Ramakrishnan, Kristin Narayan, Andrew M Wollacott, Danielle Wisheart, Alison Thomson, Brianna Close, Gregory J Babcock, Zachary Shriver and Karthik Viswanathan

>SEE POSTER

(Sibeprenlimab), an APRIL-Neutralizing IgG2

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Hershberger, et. al.

(Sibeprenlimab), an APRIL-Neutralizing IgG2

Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine Hay, Patrick Smith, Frank Engler, Jose Trevejo, Zach Shriver, David Oldach

Monoclonal Antibody, in Healthy Volunteers

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Narayan, et. al.

Monoclonal Antibody, in Healthy Volunteers

Kristin Narayan, Bharathi Sundaresh, Emily Helger, Andrew Wollacott, Karthik Viswanathan, Gregory Babcock, David Oldach, Susan Sloan

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Narayan, et. al.

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

Kristin Narayan, Bharathi Sundaresh, Emily Helger, Saskia Smits, Rienk Jeeninga, Susan Sloan, David Oldach

>SEE POSTER

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

October 23, 2018 | American Society of Nephrology (ASN)
Sloan, et. al.

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

Susan E Sloan, Frank Engler, Kristy J Szretter, James R Myette, Kristin Narayan, Bharathi L Sundaresh, Brian J G Pereira

>SEE POSTER

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

October 23, 2018 | American Society of Nephrology (ASN)
Miller, et. al.

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

Veronica M Miller, Susan E Sloan, Kristy J Szretter, James R Myette , Emily Helger, Brian J G Pereira

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk